Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of “Moderate Buy” from Analysts

Immuneering Corporation (NASDAQ:IMRX) has been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $16.50.

A number of analysts have weighed in on IMRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Immuneering in a report on Monday, March 9th. Finally, Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th.

Immuneering Stock Performance

NASDAQ:IMRX opened at $4.96 on Monday. Immuneering has a 1 year low of $1.10 and a 1 year high of $10.08. The stock has a market cap of $320.66 million, a P/E ratio of -3.59 and a beta of 0.46. The stock has a 50-day simple moving average of $5.05 and a 200-day simple moving average of $6.05.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.13. On average, equities research analysts predict that Immuneering will post -1.86 EPS for the current year.

Insider Buying and Selling at Immuneering

In other news, Director Thomas J. Schall bought 21,645 shares of Immuneering stock in a transaction dated Thursday, January 15th. The stock was acquired at an average cost of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director owned 74,530 shares of the company’s stock, valued at approximately $348,055.10. This trade represents a 40.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter Feinberg bought 20,000 shares of Immuneering stock in a transaction dated Monday, January 12th. The stock was purchased at an average cost of $4.35 per share, with a total value of $87,000.00. Following the completion of the acquisition, the director directly owned 135,441 shares in the company, valued at approximately $589,168.35. The trade was a 17.32% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 51,819 shares of company stock valued at $234,472 in the last 90 days. 22.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMRX. Jane Street Group LLC acquired a new stake in shares of Immuneering in the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Immuneering in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in Immuneering during the 3rd quarter worth $35,000. Future Financial Wealth Managment LLC acquired a new stake in Immuneering during the 3rd quarter worth $35,000. Finally, Kingsview Wealth Management LLC acquired a new stake in Immuneering during the 2nd quarter worth $47,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.